Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential.
Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease.
“This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, providers, and patients,” said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial, Samsung Bioepis. “With unwavering commitment to quality, we will continue our efforts to make our medicines more accessible so that more patients can receive the treatment they need.”
PYZCHIVA was launched by Sandoz in Europe in July 2024. PYZCHIVA became available in pre-filled pen (autoinjector) in May 2025.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – X, LinkedIn.
1 Stelara is a trademark of Johnson & Johnson. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20251105941733/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 12:00:00 CET | Press release
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.6547 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues
Shippeo Launches Shippeo AI, Turning Trusted Visibility Into Instant, Intelligent Action6.11.2025 12:00:00 CET | Press release
New AI layer, built on the industry's only SLA-backed data, empowers users to resolve supply chain issues in seconds Shippeo, the leading provider of real-time transportation visibility (RTTV), revealed Shippeo AI today, at its Visibility Now! conference. This brand new intelligent layer of the Shippeo Platform delivers trusted visibility and instant action to empower the people behind global supply chains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106263715/en/ Alongside Shippeo AI, the company revealed a series of product enhancements: an all-new eCMR (Electronic Consignment Note) system; transformed Air Visibility; a deeper user experience for Finished Vehicle Logistics (FVL); and enhanced data accessibility and UX for the Shippeo platform. This raft of innovations reinforces Shippeo’s position as the world’s most trusted multimodal visibility platform. Shippeo AI, for people who keep the world moving… faster Ship
Wireless Mobility Automotive becomes a 100% German-owned company strengthening its role as a trusted Western supplier6.11.2025 11:49:00 CET | Press release
Wireless Mobility, a leading provider of advanced cellular, automotive, smart and short-range modules, today announces that Wireless Mobility Automotive has become a wholly owned subsidiary of Wireless Mobility Holding GmbH, making the company a 100% German-owned enterprise. This milestone reinforces the company’s position as a transparent and independent Western supplier, fully aligned with the US connected vehicle ecosystem and addressing the expectations of global OEMs and tier one suppliers seeking reliable long-term partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021160513/en/ Norbert Muhrer, CEO, Wireless Mobility “This step underlines our clear commitment to transparency, independence and European quality,” said Norbert Muhrer, CEO of Wireless Mobility. “With German ownership, European engineering, and a global perspective, Wireless Mobility is ready to be the trusted Western supplier the industry has been
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 10:00:00 CET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 09:00:00 CET | Press release
Product demonstrations and presentations from subject matter experts will highlight key industry insights and the importance of smarter infrastructure to connect systems, empower choice, and unlock performance Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom